Back to Search
Start Over
Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?
- Source :
-
American Journal of Cardiology . Jan2004, Vol. 93 Issue 2, p154-158. 5p. - Publication Year :
- 2004
-
Abstract
- The Treating to New Targets (TNT) trial is a parallel-group study that has randomized 10,003 patients from 14 countries to double-blind treatment with either atorvastatin 10 or 80 mg. During the double-blind period, low-density lipoprotein (LDL) cholesterol levels are expected to reach approximate mean values of 100 mg/dl (2.6 mmol/L) for the low-dose atorvastatin group and 75 mg/dl (1.9 mmol/L) for the high-dose group. Randomized patients are expected to be followed for an average of 5 years. The primary end point is the time to occurrence of a major cardiovascular event, defined as coronary heart disease death, nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke. The large patient numbers in the TNT study and long follow-up should ensure that there is adequate power to definitively determine if reducing LDL cholesterol levels to approximately 75 mg/dl (1.9 mmol/L) can provide additional clinical benefit. [Copyright &y& Elsevier]
- Subjects :
- *LIPOPROTEINS
*CHOLESTEROL
*MYOCARDIAL infarction
*DRUG dosage
Subjects
Details
- Language :
- English
- ISSN :
- 00029149
- Volume :
- 93
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- American Journal of Cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 11885440
- Full Text :
- https://doi.org/10.1016/j.amjcard.2003.09.031